Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu[64]-25%CANF-Comb biodistribution and safety
NCT02498379Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copper-64 CANF in atherosclerosis, sponsored by Washington University School of Medicine. Primary endpoints: Biodistribution of Cu[64]-25%CANF-Comb, Dosimetry of Cu[64]-25%CANF-Comb and 1 more. Started Oct 2014; status: completed.
02
Drugs
copper-64 CANF
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02498379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498379.